Yoshito Komatsu Selected Research

Capecitabine (Xeloda)

12/2021	Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
6/2021	Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.
1/2021	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
1/2021	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report.
5/2018	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
11/2017	A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.
4/2013	Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
10/2010	Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshito Komatsu Research Topics

Disease

66	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2005
44	Neoplasms (Cancer) 01/2022 - 06/2004
36	Stomach Neoplasms (Stomach Cancer) 06/2022 - 06/2004
17	Neutropenia 12/2021 - 06/2006
12	Disease Progression 01/2022 - 01/2010
11	Adenocarcinoma 10/2021 - 09/2012
10	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2008
9	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022 - 04/2009
6	Nausea 08/2020 - 06/2006
5	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2013
5	Vomiting 08/2020 - 01/2012
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 06/2022 - 02/2005
4	Diarrhea 07/2021 - 04/2010
4	Hypertension (High Blood Pressure) 06/2015 - 04/2010
3	Microsatellite Instability 01/2022 - 02/2021
3	Hypertriglyceridemia 12/2021 - 01/2021
3	Febrile Neutropenia 12/2021 - 01/2006
3	Hyponatremia 01/2019 - 04/2010
3	Fatigue 01/2018 - 04/2010
3	Carcinoma (Carcinomatosis) 07/2011 - 06/2004
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 06/2022 - 01/2021
2	Esophageal Squamous Cell Carcinoma 03/2022 - 11/2011
2	Thrombosis (Thrombus) 01/2022 - 04/2011
2	Pain (Aches) 01/2022 - 07/2021
2	Edema (Dropsy) 01/2022 - 06/2014
2	Adenocarcinoma of Lung 07/2021 - 12/2016
2	Hypocalcemia 01/2021 - 01/2021
2	Leukopenia 08/2020 - 05/2015
2	Anemia 01/2019 - 04/2010
2	Breast Neoplasms (Breast Cancer) 01/2017 - 01/2015
2	Sigmoid Neoplasms 08/2011 - 03/2010
1	Dysgeusia (Parageusia) 06/2022
1	Pathologic Complete Response 01/2022

Drug/Important Bio-Agent (IBA)

34	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 06/2004
23	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 01/2010
21	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 11/2008
16	Bevacizumab (Avastin)FDA Link 12/2021 - 10/2010
13	Leucovorin (Folinic Acid)FDA Link 01/2022 - 09/2010
10	trifluridine tipiracil drug combinationIBA 07/2021 - 10/2012
9	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 04/2009
8	Biomarkers (Surrogate Marker)IBA 03/2022 - 06/2014
8	Capecitabine (Xeloda)FDA Link 12/2021 - 10/2010
8	Cisplatin (Platino)FDA LinkGeneric 05/2021 - 01/2006
8	regorafenibIBA 04/2020 - 06/2015
7	Gemcitabine FDA Link 01/2022 - 02/2011
7	Sunitinib (Sutent)FDA Link 11/2015 - 04/2009
6	Pharmaceutical PreparationsIBA 06/2022 - 06/2006
6	RamucirumabIBA 01/2022 - 10/2014
6	TegafurIBA 12/2021 - 07/2010
6	Cetuximab (Erbitux)FDA Link 05/2021 - 11/2008
5	Circulating Tumor DNAIBA 01/2022 - 01/2017
5	130-nm albumin-bound paclitaxelIBA 06/2021 - 06/2017
5	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 01/2017
5	Paclitaxel (Taxol)FDA LinkGeneric 12/2017 - 01/2006
4	pembrolizumabIBA 01/2022 - 01/2020
4	Formaldehyde (Formol)FDA Link 01/2022 - 01/2015
4	ParaffinIBA 01/2022 - 01/2015
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2020
4	human ERBB2 proteinIBA 01/2022 - 01/2015
4	Panitumumab (Vectibix)FDA Link 07/2021 - 01/2015
4	ErbB Receptors (EGF Receptor)IBA 07/2021 - 01/2015
4	PlatinumIBA 01/2021 - 10/2014
4	CalciumIBA 01/2021 - 01/2010
4	Monoclonal AntibodiesIBA 01/2021 - 03/2004
4	Proteins (Proteins, Gene)FDA Link 11/2019 - 04/2009
3	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2020
3	NivolumabIBA 01/2022 - 01/2019
3	AntiemeticsIBA 01/2022 - 06/2006
3	PotassiumIBA 12/2021 - 07/2010
3	Oxonic AcidIBA 12/2021 - 07/2010
3	gimeracilIBA 12/2021 - 07/2010
3	Albumin-Bound Paclitaxel FDA Link 06/2021 - 06/2017
3	S-1 plus cisplatinIBA 05/2021 - 01/2016
3	Dexamethasone (Maxidex)FDA LinkGeneric 12/2019 - 07/2015
3	afliberceptIBA 11/2019 - 01/2014
2	trastuzumab deruxtecanIBA 06/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2022 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2018
2	folfirinoxIBA 01/2022 - 06/2017
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2022 - 10/2014
2	SuspensionsIBA 06/2021 - 01/2021
2	Vitamin D FDA LinkGeneric 01/2021 - 01/2021
2	Denosumab FDA Link 01/2021 - 01/2021
2	Palonosetron (Aloxi)FDA Link 12/2019 - 07/2015
2	Everolimus FDA Link 09/2018 - 04/2010
2	AnthracyclinesIBA 07/2015 - 10/2014
2	Levoleucovorin FDA Link 08/2012 - 01/2010
2	XELOXIBA 04/2011 - 10/2010
1	ZincIBA 06/2022
1	Zinc Acetate FDA Link 06/2022
1	polaprezinc (Z 103)IBA 06/2022
1	LigandsIBA 01/2022

Therapy/Procedure

55	Drug Therapy (Chemotherapy) 06/2022 - 06/2004
48	Therapeutics 06/2022 - 10/2004
7	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 01/2008
3	Precision Medicine 01/2022 - 09/2018
2	Chemoradiotherapy 01/2022 - 11/2011
2	Drug Tapering 06/2021 - 12/2020
2	Adjuvant Chemotherapy 12/2016 - 05/2007
2	Radiotherapy 12/2013 - 04/2010